<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892407</url>
  </required_header>
  <id_info>
    <org_study_id>AG35MF001</org_study_id>
    <nct_id>NCT04892407</nct_id>
  </id_info>
  <brief_title>Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Controlled, Single-blind Study of the Safety and Effectiveness of Algeness® DF 3.5% Deep Volumizing Filler to Correct Age-related Volume Deficit in the Mid-face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Aesthetic Technologies, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Aesthetic Technologies, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, controlled study of Algeness® DF 3.5% Deep Volumizing Filler&#xD;
      comparing to Juvéderm Voluma to correct midface volume loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3:1 randomization to either study product or comparator. If subject loses volume in cheek and/or returns to baseline score at or after 12month visit, he/she may be treated with study product.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The evaluator is blinded as to patient treatment. Patients are also not told what treatment they receive.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>with ≥ 1 point improvement from baseline on Proprietary Midface Scale, a validated midface volume deficit scale as rated by a live, masked evaluator</measure>
    <time_frame>6 month</time_frame>
    <description>Statistical non inferiority of Study Product to Control by live Masked Evaluator of Subjects showing atleast a 1 point improvement. LifeSprout Midface Scale (0-4 with 0 being best and 4 being the worst/most extreme)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1+ grade Improvement on Midface Scale Live Masked Evaluator All timepoints</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>1+ grade improvement from baseline in midface scale by masked evaluator. LifeSprout Midface Scale (0-4 with 0 being best and 4 being the worst/most extreme)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline Midface Scale Live Masked Evaluator All timepoints</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>Individual endpoints for change from baseline on the Midface Scale as rated by a live, masked evaluator. LifeSprout Midface Scale (0-4 with 0 being best and 4 being the worst/most extreme)</description>
  </other_outcome>
  <other_outcome>
    <measure>GAIS Live Masked Evaluator</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>GAIS Scores of Study Product and Comparator on Global Aesthetics Improvement Scale (GAIS) by live Masked Evaluator</description>
  </other_outcome>
  <other_outcome>
    <measure>GAIS Investigator</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>GAIS Scores of Study Product and Comparator on Global Aesthetic Improvement Scale (GAIS) by Treating Investigator</description>
  </other_outcome>
  <other_outcome>
    <measure>GAIS Patient</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>GAIS Scores of Study Product and Comparator on Global Aesthetic Improvement Scale (GAIS) by Patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported FACE-Q</measure>
    <time_frame>1, 3, 9, 12, 18, 24 months</time_frame>
    <description>FACE-Q Satisfaction with Cheeks and Age Appraisal scales</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Duration</measure>
    <time_frame>1, 3, 6, 9, 12, 18, 24 months</time_frame>
    <description>Duration of treatment effect as measured on the Midface Scale by ≥1 point improvement, for those subjects who did not receive retreatment prior to the assessment timepoint at months 18 and 24.</description>
  </other_outcome>
  <other_outcome>
    <measure>Midface Photo</measure>
    <time_frame>1, 3, 6, 9, 12, 18, 24 months</time_frame>
    <description>treatment effect as measured on the Midface Scale by ≥1 point improvement as graded by a blinded photographic reviewer</description>
  </other_outcome>
  <other_outcome>
    <measure>Midface Photo Change from Baseline</measure>
    <time_frame>1, 3, 6, 9, 12, 18, 24 months</time_frame>
    <description>Individual endpoint of change from baseline score on the Midface Scale as rated by blinded photographic reviewer</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Age-Related Volume Deficit in the Mid-Face</condition>
  <arm_group>
    <arm_group_label>Algeness DF 3.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is with the Sponsor's product. The product is already CE Marked and sold for this indication for the majority of participating countries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvéderm Voluma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is with a Control product that is already CE Marked and sold for this indication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algeness® DF 3.5%</intervention_name>
    <description>dermal filler CE Mark approved for treatment of cheek and midface volume loss</description>
    <arm_group_label>Algeness DF 3.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvéderm Voluma</intervention_name>
    <description>dermal filler CE Mark approved for treatment of cheek and midface volume loss</description>
    <arm_group_label>Juvéderm Voluma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 22 years of age.&#xD;
&#xD;
          2. Subject has moderate to severe age-related volume deficit in the midface on both sides&#xD;
             of the face as rated on LifeSprout Midface Scale, a proprietary, validated mid-face&#xD;
             volume deficit scale&#xD;
&#xD;
          3. Subject willing to abstain from other facial aesthetic procedures in the mid-face&#xD;
             through the last study follow-up visit which could interfere with treatment outcomes&#xD;
             (e.g., facial fillers, skin laser and radiofrequency therapy such as Thermage,&#xD;
             chemical re-surfacing, dermabrasion, Botox injections, aesthetic facial surgery, other&#xD;
             facial treatments of the mid-face).&#xD;
&#xD;
          4. Subject willing and able to comply with study follow-up procedures and schedule.&#xD;
&#xD;
          5. Subject willing to provide written informed consent for their participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is a female of childbearing potential (e.g., not postmenopausal for at least&#xD;
             one year or has not had a hysterectomy or tubal ligation) not using medically&#xD;
             effective birth control (e.g., hormonal methods in use at least 30 days prior to&#xD;
             injection or barrier methods such as condom and spermicide in use at least 14 days&#xD;
             prior to injection) or is pregnant, lactating, or plans to become pregnant during the&#xD;
             study.&#xD;
&#xD;
          2. Subject has participated in a clinical study in which an investigational device or&#xD;
             drug was received in the 30 days prior to screening or plans to enroll in such a study&#xD;
             during the course of the current study.&#xD;
&#xD;
          3. Subject is an employee or direct relative of an employee of the investigational site&#xD;
             or Sponsor.&#xD;
&#xD;
          4. Subject who has received surgery in the mid-face (including mesh, or threads), or has&#xD;
             plans to during the study.&#xD;
&#xD;
          5. Subject has a serious or progressive disease, which, in the investigator's judgment,&#xD;
             put the subject at undue risk (e.g., uncontrolled diabetes, autoimmune pathology,&#xD;
             cardiac pathologies).&#xD;
&#xD;
          6. Subject has an acute inflammatory process or infection, or history of chronic or&#xD;
             recurrent infection or inflammation with the potential to interfere with the study&#xD;
             results or increase the risk of adverse events.&#xD;
&#xD;
          7. Subject has a disorder that may impact wound healing such as connective tissue or&#xD;
             immunosuppressive disorder.&#xD;
&#xD;
          8. Subject has a history of precancerous lesions/skin malignancies.&#xD;
&#xD;
          9. Subject has had an active skin disease within the past 6 months.&#xD;
&#xD;
         10. Subject has scars, infection, rosacea, herpes, acne, blotches or other pathology on&#xD;
             the mid-face.&#xD;
&#xD;
         11. Subject has facial hair in the mid-face that they are unwilling to remove for study&#xD;
             assessments.&#xD;
&#xD;
         12. Subject is predisposed to keloidosis or hypertrophic scarring.&#xD;
&#xD;
         13. Subject has a known history of hyper- or hypo-pigmentation in the mid-face.&#xD;
&#xD;
         14. Subject has known allergy to agarose gel, algae, phosphate buffered saline, hyaluronic&#xD;
             acid, gram positive bacterial proteins, streptococcal protein or lidocaine.&#xD;
&#xD;
         15. Subject has a known bleeding disorder.&#xD;
&#xD;
         16. Subject has received within the past week or plans to receive with 1 week before or up&#xD;
             to 1 month after any treatment high-dose Vitamin E, aspirin, anti-inflammatories,&#xD;
             antiplatelets, thrombolytics, or any other medication that could increase the risk of&#xD;
             bleeding.&#xD;
&#xD;
         17. Subject has received within the past 3 months or plans to receive during the study&#xD;
             chemotherapy agents, immunosuppressive medications, or systemic corticosteroids&#xD;
             (inhaled steroids are acceptable).&#xD;
&#xD;
         18. Subject has received within the past 12 months or plans to receive during the study&#xD;
             any injections outside of those in the study protocol including non-permanent fillers&#xD;
             (e.g., hyaluronic acid, CaHA)&#xD;
&#xD;
         19. Subject has received within the past 12 months or plans to receive during the study&#xD;
             neurotoxin on the face below the orbital rim (forehead is acceptable).&#xD;
&#xD;
         20. Subject has received at any time or plans to receive during the study a permanent&#xD;
             filler (e.g., polylactic acid, PMMA, silicone) on the face.&#xD;
&#xD;
         21. Subject has received within the past 6 months or plans to receive during the study&#xD;
             dermal resurfacing procedures or non-invasive skin tightening on the face.&#xD;
&#xD;
         22. Subject has received in the past 4 weeks or plans to receive during the study&#xD;
             prescription facial wrinkle therapies (RENOVA), topical steroids, skin irritating&#xD;
             topical preparations, or self-tanning agents on the face.&#xD;
&#xD;
         23. Subject has a known history of or plans during the study rapid weight loss/gain (5% of&#xD;
             body weight).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HEATHER ASTLEY</last_name>
    <phone>7813292993</phone>
    <email>hastley@healthpolicyassociates.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>J. Vandeputte, Plastische Chirurgie</name>
      <address>
        <city>Oudenaarde</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>info@jvdp.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MEDITI</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>THINKIN</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All summary results will be posted to this website. Safety results will be shared with medical monitor and study physicians.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

